Treatment of Newly Diagnosed AML in Older Adults (≥55) with IDH2 Mutation Not Eligible for Conventional Induction

Clinical Scenario

This protocol addresses older adults aged 55 and above with a new diagnosis of acute myeloid leukemia who carry an IDH2 mutation. These patients are considered appropriate candidates for antileukemic therapy, but their clinical profile places conventional intensive induction and postremission chemotherapy outside the recommended approach.

Key Patient Characteristics

Age ≥55 Newly diagnosed AML IDH2 mutation Not for conventional induction

The IDH2 mutation status and patient age together shape the choice of antileukemic regimen for this population, distinguishing their management from younger patients or those without this molecular finding.

Treatment Approach (Partial Overview)

Current evidence-based guidance for this population centres on hypomethylating agent (HMA)-based regimens. One preferred path involves azacitidine used as monotherapy; an alternative involves an HMA combined with a second targeted agent.

The complete regimen selection algorithm, sequencing rationale, and full evidence summaries are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/bloodadvances.2025017934

For older adults with newly diagnosed AML and an IDH2 mutation considered appropriate for ALT but not for conventional induction and postremission therapy, the ASH guideline panel suggests azacitidine monotherapy over azacitidine in combination with enasidenib (conditional recommendation based on low certainty in the evidence of effects ⨁⨁◯◯).

For older adults with newly diagnosed AML and an IDH2 mutation considered appropriate for ALT but not for conventional induction and postremission therapy, the ASH guideline panel suggests HMA in combination with venetoclax over HMA in combination with enasidenib (conditional recommendation based on very low certainty in the evidence of effects ⨁◯◯◯).

View source ↗